Imexpharm Corporation
Khanh Hoang Tran is a seasoned professional in the pharmaceutical industry, currently serving as a Product Manager at Imexpharm Corporation since January 2022, where responsibilities include driving sales and market penetration for key product groups such as Amoxicillin, Cefalexin, and Paracetamol across both OTC and ETC channels in Vietnam. Prior experience includes a role as Business Development Manager at F.D&C Pharmaceutical Company Limited, focusing on sales strategies for excipients; Trade Marketing Executive at DKSH, managing trade marketing for Efferalgan and Upsa C; and Sales Consultant at Zuellig Pharma Vietnam Ltd., overseeing key principles within the OTC channel. Khanh holds a Bachelor's degree in Management Information Systems from the University Of Economics Ho Chi Minh City, a Bachelor of Science in Pharmacy with a focus on Pharmaceutical Marketing and Management from Lac Hong University, and an Intermediate Degree in Pharmacy from Cuu Long College.
This person is not in any teams
Imexpharm Corporation
Established in 1977 in Dong Thap Province, Vietnam, Imexpharm has consistently pursued excellence in quality as its unwavering commitment, dedicated to providing exceptional healthcare products of the highest quality, safety, and efficacy for patients and the community. Driven by a commitment to excellence, Imexpharm has, for nearly a half century, consistently invested in research and development, upgraded technology, established modern technical infrastructure, optimized production processes, and invested in human resources to ensure compliance with the most advanced world standards, including EU-GMP. Our dedication is reflected in our current ownership of three EU-GMP factories boasting a total of 11 production lines. This positions Imexpharm as the pharmaceutical manufacturer with the largest cluster of EU-GMP factories and the most EU-GMP production lines in Vietnam. In 2020, Imexpharm received investment from SK Investment, a member of the SK Group, the second-largest economic conglomerate in South Korea and listed in the Global Fortune 500. With a strong financial foundation and international management experience from SK Investment, Imexpharm will become the largest pharmaceutical manufacturing company in Vietnam, helping to meet the domestic and export market demands.